



**Global Reach, Local Care:
Scaling In-home Trial Delivery
Across 10 Evolving Protocols**

An ATTR-CM Case Study

ATTR-CM:**An Urgent Need For Inclusive Trial Access**

Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is a rare, progressive, and often fatal condition caused by the accumulation of misfolded transthyretin (TTR) proteins as amyloid deposits in the heart. This leads to a gradual decline in cardiac function, reduced mobility, and eventual heart failure. Given the debilitating nature of the condition, patients often face significant barriers to participating in traditional clinical trials, including limited mobility, geographic distance, and the need for frequent in-person visits.

This **global Phase 3, randomized, double-blinded study** - sponsored by a multinational biopharmaceutical company - aimed to evaluate the safety and efficacy of an investigational drug designed to lower circulating TTR levels and reduce amyloid formation in the myocardium.

HTS: Centering Trial Delivery Around Patients

MRN's Home Trial Support (HTS) played a central role in improving trial access for patients worldwide. By conducting study visits directly in participants' homes, MRN removed barriers to participation, ensuring patients could continue in the trial regardless of where they lived or mobility. Visits were conducted at patients' primary residences, secondary homes, or even temporary holiday locations, with care adjusted to their needs and lifestyle.

*Case Study Outcome***Indication: ATTR-CM:**

Locations: Australia, Austria, Brazil, Canada, France, Germany, Italy, Portugal, Spain, Sweden, UK, US.

Phase 3 study, enrolling participants aged 18–90, designed to test the investigational drug's ability to treat ATTR-CM by lowering TTR levels and slowing disease progression. Launched in 2019 this program has become one of MRN's most complex and far-reaching studies to date, demanding continuous adaptation across shifting protocols, global sites, and an evolving patient population.

12	countries across the globe
111	sites trained and onboarded to utilize HTS
95%+	visit success rate
23,000+	HTS visits completed to date
1000+	patients using Home Trial Support to facilitate their participation



Real-World Flexibility & Precision

MRN has delivered over **23,000 in-home visits** for this study so far, supporting patients from early enrollment through to later phases. Visits began with routine lab work, including blood draws, and later expanded to investigational product administration. Our flexible approach ensures continuity and quality of data throughout the length of the trial. Examples of MRN's flexibility include:

- Adapted visit frequency and logistics in response to evolving protocol requirements
- Ensured uninterrupted participation, even as patients' lives required additional flexibility
- Supported patients at second homes or travelling for domestic or international holidays.

Adapting To Lab Kit Distribution Changes

Midway through the study, the central lab used by the sponsor modified its kit distribution process. To be able to scale efficiently and to manage new Brexit restrictions, MRN's supply management team rapidly implemented a new logistics solution allowing MRN healthcare professionals to maintain uninterrupted delivery of visits, safeguard sample integrity, and ensure protocol compliance all without burdening patients or sites.

Operational adjustments like this are a reminder that trial delivery must be designed for adaptability. In complex, long-running global studies, **the ability to adapt without disrupting the patient experience or data collection is not optional, it's essential.**

Close Collaboration with Sites

MRN worked closely with all Site Coordinators and CRAs to ensure alignment and quality across all participating sites. MRN provided active site engagement, including weekly recap emails and routine calls to maintain consistency, support patient experience, and ensure study continuity.

Adapting Across Multiple Protocols & Geographies

The study included **ten distinct protocols, with variation across countries and visit schedules.** Visit frequency shifted from weekly to monthly over time, depending on the protocol version and patient cohort. MRN's global coordination allowed these transitions to happen smoothly, while maintaining adherence to local regulations and the overarching trial framework.

Early Engagement Drives Retention

Proactive early engagement with both the sponsor and CRO ensured site readiness and supported high patient retention over multiple years. MRN's flexibility, responsiveness, and experience in complex international delivery were essential to sustaining continuity and momentum throughout the trial.

A Project That Set A New Benchmark

This study stands out not only for its global reach and scale but for the strength of the team behind it. Project Managers, Visit Delivery Associates, field healthcare professionals, and operations leaders came together to deliver one of MRN's largest and most logistically complex projects to date, all while delivering over **23,000 HTS visits across 10 distinct protocols in 12 countries, maintaining a visit success rate of 95%+.**

That's 23,000 moments of access. 23,000 opportunities for a patient to participate in a clinical trial when it might not have been possible otherwise. Through collaboration, adaptability, and patient-first delivery, MRN helped advance critical research and demonstrated what's possible when clinical trials are designed around patients.

Delivering Excellence In A Changing Landscape

With a global footprint, multiple protocol pathways, and an evolving patient population, this study required seamless execution and true cross-functional collaboration. MRN's agility and consistency under pressure were instrumental in ensuring high-quality visit delivery and long-term trial success.

Supporting Sites Behind The Scenes

MRN maintained close communication with site-based CRAs and Coordinators throughout the study, helping resolve documentation access issues, manage user permissions, and support data entry processes particularly during periods of staff turnover. **MRN provided a high level of site engagement, contributing to improved visit success and patient satisfaction.**

Collaboration, Adaptation & Clinical Success

Through regular engagement and transparent reporting, MRN helped maintain shared visibility across stakeholders, supporting collaborative decision-making and a steady pace of delivery throughout the trial.

Key Collaboration Highlights:

- Weekly meetings with the CRO project management team
- Bi-weekly tri-party meetings with the sponsor and CRO
- Monthly "Advanced Study Level Reports" providing detailed tracking metrics
- Quarterly governance roundtables with MRN leadership and external stakeholders.

Delivering Community-Based Trials

focused on patients, focused on results

With our Home Trial Support services, we remove participation barriers by bringing trials to patients where they live, creating convenience and comfort that results in **increased recruitment and retention**.




Our project management and visit delivery team have a strong understanding of **global regulations for in-home care** and are able to collaborate directly with the Sponsor and country managers to expand services, ensuring patients receive necessary home visits as their needs grow.


“We act as a single provider with global delivery. This means we can scale quickly and efficiently to deliver where patients live.”


Stuart Redding, CEO, MRN





Our offices


 **UK**
Medical Research Network Ltd
Milton Keynes

 **USA**
Medical Research Network Inc.
Deerfield IL

 **Spain**
Medical Research Network
Madrid

 **Germany**
Medical Research Network Germany GmbH
Stuttgart-Vaihingen

 **Japan**
Medical Research Network Japan KK
Tokyo

 **France**
Medical Research Network,
Lyon

 enquiries@themrn.co.uk

 www.themrn.io

